Passage Bio Q3 net loss $19.3M; 4 patients enrolled in FTD-GRN Cohort 2; cash to Q2 2026

Passage BIO, Inc.

2024-Q3 EPS reported -$0.87

Net loss $19.3M ($0.31/share) vs $27.1M loss a year ago; R&D expenses fell to $8.7M from $15.1M.
Cash and securities $84.8M at Sept 30, 2024; expected runway to end Q2 2026.
Enrolled 4 patients in Cohort 2 of upliFT-D trial; 12-month Cohort 1 and interim Cohort 2 data due 1H25.
Interim Cohort 1 data: PBFT02 raised CSF progranulin for up to 12 months; no serious adverse events with enhanced immunosuppression.
Appointed Tom Kassberg (Ultragenyx CBO) to board of directors and Audit Committee.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.